Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Location: Switzerland
Employees: 1-10
Total raised: $101.75M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 22.07.2025 | Neva SGR | nevasgr.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.07.2025 | Series B | $99.15M | Angelini V... |
| 28.03.2022 | Grant | $2.6M | - |
Mentions in press and media 12
| Date | Title | Description |
| 06.03.2026 | Investments in women-led companies set a clear record | The Swiss Startup ecosystem is clearly male dominated. According to the Startupticker database, female CEOs accounted only for 15.3% of startup foundations from 2021 to 2025. However, this share has increased compared with earlier years, w... |
| 26.01.2026 | New leadership for ICT and Life Sciences Swiss startups | Timo Müller, Co-founder and former VP Product at Voliro, has been promoted to the posision of CEO, succeeding Florian Gutzwiller, who will transition into a strategic role as member of the Board of Directors. The leadership transition refl... |
| 27.10.2025 | Sweden’s Lithea secures €851k to advance tumour-targeted therapy for childhood bone cancer | Lithea, a Lund-based company working on new ways to treat cancer by delivering medicine directly into tumours, has successfully raised €851k from its current investors to continue developing their drug delivery system and prepare its lead p... |
| 13.10.2025 | Clinical milestones bring startups closer to launching new therapies | Following a positive meeting with the U.S. Food and Drug Administration (FDA), Oculis is advancing Privosegtor, a new peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis ... |
| 12.07.2025 | Swiss Biotech Secures Major Funding for Advanced Cancer Treatments | Swiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce... |
| 11.07.2025 | NUCLIDIUM raises €84M Series B to advance copper-based cancer therapies | NUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding. Leveraging copper is... |
| 10.07.2025 | HighLight Capital joins global investors in backing NUCLIDIUM | - |
| 10.07.2025 | Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer | Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million. The round was led b... |
| 10.07.2025 | Nuclidium Raises €84M in Series B Funding | Nuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding The round was co-led by Angelini Ventures, Kurma Growth Opportuniti... |
| 10.07.2025 | CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform | NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy... |
Show more